Adalimumab (d2e7)    (DrugBank: Adalimumab)

2 diseases
IDDisease name (Link within this page)Number of trials
96Crohn disease1
271Ankylosing spondylitis2

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,209 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00055523
(ClinicalTrials.gov)
April 20024/3/2003A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's DiseaseA Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's DiseaseCrohn's DiseaseDrug: Adalimumab (D2E7)AbbottNULLCompleted18 Years75 YearsBoth300Phase 2United States

271. Ankylosing spondylitis    [ 531 clinical trials,   343 drugs,   (DrugBank: 66 drugs),   41 drug target genes,   141 drug target pathways]
Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 531 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00085644
(ClinicalTrials.gov)
January 200410/6/2004Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing SpondylitisA Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing SpondylitisAnkylosing SpondylitisBiological: adalimumab (D2E7);Biological: placeboAbbottNULLCompleted18 YearsN/AAll315Phase 3United States
2NCT00195819
(ClinicalTrials.gov)
December 200316/9/2005Safety and Efficacy of Adalimumab in Patients With Active Ankylosing SpondylitisA Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing SpondylitisAnkylosing SpondylitisBiological: adalimumab (D2E7);Biological: placeboAbbottNULLCompleted18 YearsN/AAll82Phase 3Canada;United States